Description
Dermatology Drugs Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area; By Drug Class; By Route of Administration (Topical, Oral, Parenteral); By Distribution Channel; By Region; Segment Forecast, 2023 - 2032 The global dermatology drugs market size is expected treach USD 50.47 billion by 2032, according ta new study by Polaris Market Research. The report “Dermatology Drugs Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area; By Drug Class; By Route of Administration (Topical, Oral, Parenteral); By Distribution Channel; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight intcurrent market dynamics and provides analysis on future market growth.
The dermatology drugs market is experiencing a surge in demand due ta growing burden of dermatology diseases globally, with increasing prevalence rates. Increased awareness of disease progression and etiology has increased, leading ta higher demand for effective treatments. The rise in the elderly population has contributed significantly tthe market's growth.
Older individuals are more susceptible tskin-related disorders due tvarious physiological changes associated with aging. For instance, changes in the connective tissue, reduction in skin strength and elasticity, and decrease in sebaceous gland secretions are common in aging individuals, leading ta higher demand for dermatology drugs.
Dermatology is a diverse specialty encompassing disorders and diseases of the skin, mucous membrane, hair, and nails. Conditions in this category include acne, multiple inflammatory dermatoses, skin cancers, autoimmune disease, occupational dermatitis, and contact dermatitis. It’s a highly fragmented therapeutic area, under which comes acne, rosacea, psoriasis, atopic dermatitis, and other disorders.
Biologics are becoming a popular treatment option for dermatological conditions due ttheir effectiveness and targeted approach, with many drugs approved by regulatory bodies and more in development. Patients alsincreasingly prefer topical treatments over systemic medications due tconvenience, fewer side effects, and targeted approach, leading ta rise in the demand for topical dermatology drugs. The rising demand in emerging markets, increasing adoption of combination therapies, and focus on personalized medicine are alsdriving growth in the industry.
For instance, In March 2022, Johnson & Johnson's Janssen Pharmaceutical Companies initiated a prospective clinical trial named VISIBLE tevaluate the safety and efficacy of a drug for people of color suffering from moderate tsevere plaque and/or scalp psoriasis.
Dermatology Drugs Market Report Highlights
Psoriasis segment is accounted for the largest market share because of the increasing the prevalence of psoriasis globally and manufacturers launching new medications for the treatment.
Corticosteroids segment holds the highest CAGR of the market. in various conditions of skin disorders topical corticosteroids are used widely in conditions such as psoriasis, dermatitis, acne and others.
parenteral segment holds the largest share in the market, due tvarious biologics are available for the dermatological conditions, and biologics are generally taken through the parenteral route of administration.
Hospital pharmacy segment dominated the market and willing tcontinue its dominance over the forecast period. Nowadays peoples are aware with the skin diseases that’s why increased in the patient visits thospitals and sales of prescription drugs increased.
North America holds the largest market share in the market and expected tmaintain its dominance during the forecast period. Increased in the awareness of skin diseases and raising the treatment and key players making the developments in this market fuels the growth of the region.
The global key market players include Lupin, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi, Amgen Inc., Lilly, AstraZeneca, AbbVie Inc., Johnson & Johnson Private Limited, LEO Pharma A/S, Merck & Co. Inc., Bausch Health Companies Inc., and Bristol-Myers Squibb Company.
Polaris Market Research has segmented the dermatology drugs market report based on therapeutic area, drug class, route of administration, distribution channel, and region:
Dermatology Drugs, Therapeutic Area Outlook (Revenue - USD Billion, 2019 - 2032)
Acne
Atopic Dermatitis
Psoriasis
Rosacea
Others
Dermatology Drugs, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)
Anti-infectives
Corticosteroids
Anti-acne
Calcineurin Inhibitors
Retinoids
Others
Dermatology Drugs, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)
Topical
Oral
Parenteral
Dermatology Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Dermatology Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Show more
Table of Contents
1. Introduction 1.1. Report Description 1.1.1. Objectives of the Study 1.1.2. Market Scope 1.1.3. Assumptions 1.2. Stakeholders 2. Executive Summary 2.1. Market Highlights 3. Research Methodology 3.1. Overview 3.1.1. Data Mining 3.2. Data Sources 3.2.1. Primary Sources 3.2.2. Secondary Sources 4. Global Dermatology Drugs Market Insights 4.1. Dermatology Drugs – Industry Snapshot 4.2. Dermatology Drugs Market Dynamics 4.2.1. Drivers and Opportunities 4.2.1.1. Increasing Elderly Population 4.2.1.2. Rise in Clinical Studies 4.2.2. Restraints and Challenges 4.2.2.1. High Cost 4.3. Porter’s Five Forces Analysis 4.3.1. Bargaining Power of Suppliers (Moderate) 4.3.2. Threats of New Entrants: (Low) 4.3.3. Bargaining Power of Buyers (Moderate) 4.3.4. Threat of Substitute (Moderate) 4.3.5. Rivalry among existing firms (High) 4.4. PESTLE Analysis 4.5. Dermatology Drugs Industry Trends 4.6. Value Chain Analysis 4.7. COVID-19 Impact Analysis 5. Global Dermatology Drugs Market, by Therapeutic Area 5.1. Key Findings 5.2. Introduction 5.2.1. Global Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 5.3. Acne 5.3.1. Global Dermatology Drugs Market, by Acne, by Region, 2019-2032 (USD Billion) 5.4. Atopic Dermatitis 5.4.1. Global Dermatology Drugs Market, by Atopic Dermatitis, by Region, 2019-2032 (USD Billion) 5.5. Psoriasis 5.5.1. Global Dermatology Drugs Market, by Psoriasis, by Region, 2019-2032 (USD Billion) 5.6. Rosacea 5.6.1. Global Dermatology Drugs Market, by Rosacea, by Region, 2019-2032 (USD Billion) 5.7. Others 5.7.1. Global Dermatology Drugs Market, by Others, by Region, 2019-2032 (USD Billion) 6. Global Dermatology Drugs Market, by Drug Class 6.1. Key Findings 6.2. Introduction 6.2.1. Global Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 6.3. Anti-infectives 6.3.1. Global Dermatology Drugs Market, by Anti-infectives, by Region, 2019-2032 (USD Billion) 6.4. Corticosteroids 6.4.1. Global Dermatology Drugs Market, by Corticosteroids, by Region, 2019-2032 (USD Billion) 6.5. Anti-acne 6.5.1. Global Dermatology Drugs Market, by Anti-acne, by Region, 2019-2032 (USD Billion) 6.6. Calcineurin Inhibitors 6.6.1. Global Dermatology Drugs Market, by Calcineurin Inhibitors, by Region, 2019-2032 (USD Billion) 6.7. Retinoids 6.7.1. Global Dermatology Drugs Market, by Retinoids, by Region, 2019-2032 (USD Billion) 6.8. Others 6.8.1. Global Dermatology Drugs Market, by Others, by Region, 2019-2032 (USD Billion) 7. Global Dermatology Drugs Market, by Route of Administration 7.1. Key Findings 7.2. Introduction 7.2.1. Global Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 7.3. Topical 7.3.1. Global Dermatology Drugs Market, by Topical, by Region, 2019-2032 (USD Billion) 7.4. Oral 7.4.1. Global Dermatology Drugs Market, by Oral, by Region, 2019-2032 (USD Billion) 7.5. Parenteral 7.5.1. Global Dermatology Drugs Market, by Parenteral, by Region, 2019-2032 (USD Billion) 8. Global Dermatology Drugs Market, by Distribution Channel 8.1. Key Findings 8.2. Introduction 8.2.1. Global Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 8.3. Hospital Pharmacy 8.3.1. Global Dermatology Drugs Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion) 8.4. Retail Pharmacy 8.4.1. Global Dermatology Drugs Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion) 8.5. Online Pharmacy 8.5.1. Global Dermatology Drugs Market, by Online Pharmacy, by Region, 2019-2032 (USD Billion) 9. Global Dermatology Drugs Market, by Geography 9.1. Key findings 9.2. Introduction 9.2.1. Dermatology Drugs Market Assessment, By Geography, 2019-2032 (USD Billion) 9.3. Dermatology Drugs Market – North America 9.3.1. North America: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.3.2. North America: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.3.3. North America: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.3.4. North America: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.3.5. Dermatology Drugs Market – U.S. 9.3.5.1. U.S.: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.3.5.2. U.S.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.3.5.3. U.S.: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.3.5.4. U.S.: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.3.6. Dermatology Drugs Market – Canada 9.3.6.1. Canada: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.3.6.2. Canada: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.3.6.3. Canada: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.3.6.4. Canada: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.4. Dermatology Drugs Market – Europe 9.4.1. Europe: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.4.2. Europe: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.4.3. Europe: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.4.4. Europe: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.4.5. Dermatology Drugs Market – UK 9.4.5.1. UK: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.4.5.2. UK: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.4.5.3. UK: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.4.5.4. UK: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.4.6. Dermatology Drugs Market – France 9.4.6.1. France: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.4.6.2. France: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.4.6.3. France: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.4.6.4. France: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.4.7. Dermatology Drugs Market – Germany 9.4.7.1. Germany: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.4.7.2. Germany: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.4.7.3. Germany: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.4.7.4. Germany: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.4.8. Dermatology Drugs Market – Italy 9.4.8.1. Italy: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.4.8.2. Italy: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.4.8.3. Italy: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.4.8.4. Italy: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.4.9. Dermatology Drugs Market – Spain 9.4.9.1. Spain: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.4.9.2. Spain: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.4.9.3. Spain: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.4.9.4. Spain: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.4.10. Dermatology Drugs Market – Netherlands 9.4.10.1. Netherlands: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.4.10.2. Netherlands: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.4.10.3. Netherlands: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.4.10.4. Netherlands: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.4.11. Dermatology Drugs Market – Russia 9.4.11.1. Russia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.4.11.2. Russia.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.4.11.3. Russia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.4.11.4. Russia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.5. Dermatology Drugs Market – Asia Pacific 9.5.1. Asia Pacific: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.5.2. Asia Pacific: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.5.3. Asia Pacific: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.5.4. Asia Pacific: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.5.5. Dermatology Drugs Market – China 9.5.5.1. China: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.5.5.2. China.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.5.5.3. China: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.5.5.4. China: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.5.6. Dermatology Drugs Market – India 9.5.6.1. India: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.5.6.2. India.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.5.6.3. India: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.5.6.4. India: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.5.7. Dermatology Drugs Market – Japan 9.5.7.1. Japan: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.5.7.2. Japan.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.5.7.3. Japan: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.5.7.4. Japan: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.5.8. Dermatology Drugs Market – Malaysia 9.5.8.1. Malaysia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.5.8.2. Malaysia.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.5.8.3. Malaysia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.5.8.4. Malaysia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.5.9. Dermatology Drugs Market – Indonesia 9.5.9.1. Indonesia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.5.9.2. Indonesia.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.5.9.3. Indonesia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.5.9.4. Indonesia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.5.10. Dermatology Drugs Market – South Korea 9.5.10.1. South Korea: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.5.10.2. South Korea.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.5.10.3. South Korea: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.5.10.4. South Korea: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.6. Dermatology Drugs Market – Middle East & Africa 9.6.1. Middle East & Africa: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.6.2. Middle East & Africa: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.6.3. Middle East & Africa: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.6.4. Middle East & Africa: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.6.5. Dermatology Drugs Market – Saudi Arabia 9.6.5.1. Saudi Arabia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.6.5.2. Saudi Arabia: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.6.5.3. Saudi Arabia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.6.5.4. Saudi Arabia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.6.6. Dermatology Drugs Market – South Africa 9.6.6.1. South Africa: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.6.6.2. South Africa: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.6.6.3. South Africa: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.6.6.4. South Africa: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.6.7. Dermatology Drugs Market – Israel 9.6.7.1. Israel: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.6.7.2. Israel: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.6.7.3. Israel: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.6.7.4. Israel: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.6.8. Dermatology Drugs Market – UAE 9.6.8.1. UAE: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.6.8.2. UAE: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.6.8.3. UAE: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.6.8.4. UAE: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.7. Dermatology Drugs Market – Latin America 9.7.1. Latin America: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.7.2. Latin America: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.7.3. Latin America: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.7.4. Latin America: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.7.5. Dermatology Drugs Market – Mexico 9.7.5.1. Mexico: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.7.5.2. Mexico: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.7.5.3. Mexico: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.7.5.4. Mexico: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.7.6. Dermatology Drugs Market – Brazil 9.7.6.1. Brazil: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.7.6.2. Brazil: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.7.6.3. Brazil: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.7.6.4. Brazil: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 9.7.7. Dermatology Drugs Market – Argentina 9.7.7.1. Argentina: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion) 9.7.7.2. Argentina: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion) 9.7.7.3. Argentina: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion) 9.7.7.4. Argentina: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion) 10. Competitive Landscape 10.1. Expansion and Acquisition Analysis 10.1.1. Expansion 10.1.2. Acquisitions 10.2. Partnerships/Collaborations/Agreements/Exhibitions 11. Company Profiles 11.1. Lupin 11.1.1. Company Overview 11.1.2. Financial PerRoute of Administrationance 11.1.3. Distribution Channel Benchmarking 11.1.4. Recent Development 11.2. Novartis AG 11.2.1. Company Overview 11.2.2. Financial PerRoute of Administrationance 11.2.3. Distribution Channel Benchmarking 11.2.4. Recent Development 11.3. F. Hoffmann-La Roche Ltd 11.3.1. Company Overview 11.3.2. Financial PerRoute of Administrationance 11.3.3. Distribution Channel Benchmarking 11.3.4. Recent Development 11.4. Pfizer Inc 11.4.1. Company Overview 11.4.2. Financial PerRoute of Administrationance 11.4.3. Distribution Channel Benchmarking 11.4.4. Recent Development 11.5. Sanofi 11.5.1. Company Overview 11.5.2. Financial PerRoute of Administrationance 11.5.3. Distribution Channel Benchmarking 11.5.4. Recent Development 11.6. Amgen Inc 11.6.1. Company Overview 11.6.2. Financial PerRoute of Administrationance 11.6.3. Distribution Channel Benchmarking 11.6.4. Recent Development 11.7. Lilly 11.7.1. Company Overview 11.7.2. Financial PerRoute of Administrationance 11.7.3. Distribution Channel Benchmarking 11.7.4. Recent Development 11.8. AstraZeneca 11.8.1. Company Overview 11.8.2. Financial PerRoute of Administrationance 11.8.3. Distribution Channel Benchmarking 11.8.4. Recent Development 11.9. AbbVie Inc. 11.9.1. Company Overview 11.9.2. Financial PerRoute of Administrationance 11.9.3. Distribution Channel Benchmarking 11.9.4. Recent Development 11.10. Johnson & Johnson Private Limited 11.10.1. Company Overview 11.10.2. Financial PerRoute of Administrationance 11.10.3. Distribution Channel Benchmarking 11.10.4. Recent Development 11.11. LEO Pharma A/S 11.11.1. Company Overview 11.11.2. Financial PerRoute of Administrationance 11.11.3. Distribution Channel Benchmarking 11.11.4. Recent Development 11.12. Merck & Co. Inc 11.12.1. Company Overview 11.12.2. Financial PerRoute of Administrationance 11.12.3. Distribution Channel Benchmarking 11.12.4. Recent Development 11.13. Bausch Health Companies Inc 11.13.1. Company Overview 11.13.2. Financial PerRoute of Administrationance 11.13.3. Distribution Channel Benchmarking 11.13.4. Recent Development 11.14. Bristol-Myers Squibb Company 11.14.1. Company Overview 11.14.2. Financial PerRoute of Administrationance 11.14.3. Distribution Channel Benchmarking 11.14.4. Recent Development